Advances in Hematology

Total Page:16

File Type:pdf, Size:1020Kb

Advances in Hematology ADVANCES IN HEMATOLOGY Current Developments in the Management of Hematologic Disorders Hematology Section Editor: Craig M. Kessler, MD What Hematologists Need to Know About Acute Hepatic Porphyria Manisha Balwani, MD, MS Associate Professor Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York, New York H&O What is porphyria? H&O How common is acute hepatic porphyria? MB The porphyrias encompass a group of inherited MB Based on estimates from Western Europe, the metabolic disorders that result from a deficiency of one of combined prevalence of the acute hepatic porphyrias the enzymes in the heme biosynthetic pathway. These are among the white population is approximately 1 in genetic disorders; they can be inherited in an autosomal 200,000. These disorders are more common in certain dominant or recessive X-linked pattern; or they may be parts of the world because of founder mutations. For sporadic, as with porphyria cutanea tarda. example, the carrier frequency of acute intermittent porphyria is much higher in the Scandinavian countries, H&O How many types of porphyria exist? and variegate porphyria is much more common in South Africa.1 MB There are 8 different kinds of porphyria. These may be Even where the incidence is high, symptoms related classified as hepatic or erythropoietic based on the primary to these disorders remain rare. In fact, most patients who site of accumulation of porphyrins, but more commonly inherit a genetic change do not manifest symptoms of the they are classified clinically as acute or cutaneous. The acute disorder—the disease remains latent in a vast majority of hepatic porphyrias include acute intermittent porphyria these patients. Based on studies from Europe, we have (the most common form), hereditary coproporphyria, and estimated that only about 10% of patients who have a variegate porphyria, which are autosomal dominant in mutation in one of these genes will actually present with inheritance. Aminolevulinic acid dehydratase deficiency symptoms. In fact, a more recent study using genomic porphyria is autosomal recessive and very rare, with fewer and exomic databases suggests that having a mutation than 10 cases reported worldwide. in one of these genes is much more common than we The cutaneous porphyrias include porphyria cutanea initially thought, making the penetrance of this disorder tarda, which is the most common form; erythropoietic much lower.2 protoporphyria; X-linked protoporphyria; and congenital erythropoietic porphyria. These can present with blistering H&O Could you talk in more detail about the skin lesions or with nonblistering photosensitivity. Her- causes of acute hepatic porphyria? editary coproporphyria and variegate porphyria also can present with blistering skin lesions similar to those MB As I mentioned, a genetic change leads to a deficiency seen in porphyria cutanea tarda. Patients with cutaneous in one of the enzymes in the heme biosynthetic pathway. porphyria rarely present to hematologists, which is why I Because these are almost always autosomal dominant dis- am focusing on the acute hepatic porphyrias. orders, patients have approximately half-normal enzyme 858 Clinical Advances in Hematology & Oncology Volume 14, Issue 11 November 2016 Uncontrolled Complement Amplication Succinyl Coenzyme A Glycine Hematology X-linked protoporphyria, X-linked sideroblastic anemia Aminolevulinic acid synthase Negative feedback δ-Aminolevulinic acid Aminolevulinic acid dehydratase deciency porphyria Aminolevulinic acid dehydratase Porphobilinogen Acute intermittent porphyria Hydroxymethylbilane synthase Hydroxymethylbilane Congenital erythropoietic porphyria Uroporphyrinogen III synthase Nonenzymatic Uroporphyrinogen III Uroporphyrinogen I—uroporphyrin I Porphyria cutanea tarda, hepatoerythropoietic porp hyria Uroporphyrinogen decarboxylase Coproporphyrinogen III Coproporphyrinogen I—coproporphyrin I Hereditary coproporphyria Coproporphyrinogen oxidase Protoporphyrinogen IX Variegate porphyria Protoporphyrinogen oxidase Protoporphyrin IX Erythropoietic protoporphyria Ferrochelatase Negative feedback Heme Figure. The heme biosynthetic pathway. Enzymes are in italics. activity. Under normal circumstances, this is sufficient managed correctly. Delays in diagnosis and treatment for heme synthesis. The presence of certain precipitating may result in chronic complications that can be very factors, however, can lead to symptomatic disease. The debilitating for patients. most common precipitating factors are drugs, fasting, hormonal changes, stress, and illness. Women are much H&O What are the symptoms of porphyria, and more likely than men to manifest symptoms, presumably what complications can occur? because of hormonal factors. All of these factors markedly increase the demand MB One of the most common symptoms is acute for hepatic heme, and the decreased hepatic free heme abdominal pain that is poorly localized and very induces the synthesis of δ-aminolevulinic acid synthase severe. Because the pain is neuropathic, it often is not 1 (ALAS1)—the first enzyme in the heme biosynthetic accompanied by fever or leukocytosis. Patients also may pathway—by a negative feedback mechanism (Figure). experience nausea, vomiting, constipation, or pain in the Because of the approximately half-normal enzyme activity chest or back. They also can have significant autonomic in these acute hepatic porphyrias, the marked overexpres- dysfunction, including tachycardia and hypertension. sion of ALAS1 results in the increased production and Patients also may develop paresis or acute motor subsequent accumulation of the neurotoxic porphyrin neuropathy, and may experience changes in mental status, precursors, aminolevulinic acid (ALA) and urine porpho- such as behavioral changes, agitation, or hallucinations. bilinogen (PBG). These porphyrin precursors are thought If patients do not receive appropriate treatment, there to be neurotoxic and responsible for the multisystemic is a possibility that neuropathy could progress and even manifestations of this disorder. lead to respiratory paralysis. Recent reports have shown that during acute attacks, some patients develop posterior H&O What is the prognosis for someone with reversible encephalopathy syndrome, which can be acute porphyria? diagnosed on magnetic resonance imaging of the brain and can give a clue to the diagnosis. One important MB The overall prognosis is good because specific treat- thing to note is that no sign or symptom is universal, and ment is available, but symptoms must be recognized and presentations are often atypical. Clinical Advances in Hematology & Oncology Volume 14, Issue 11 November 2016 859 Another important early sign of this disorder is avoid the triggering factors that could precipitate acute hyponatremia. This is often seen when patients present attacks. with acute attacks, and can be one of the first clues leading Hematology to diagnosis. Hyponatremia presumably occurs because H&O Does porphyria often get confused with of the syndrome of inappropriate antidiuretic hormone other diseases? secretion (SIADH) or because of loss of sodium in the gastrointestinal tract or kidneys. It is very important to MB The most common presenting symptoms of this monitor patients with hyponatremia because they can disorder—abdominal pain, nausea, and vomiting—are develop seizures. common, nonspecific symptoms. As you can imagine, this Additional findings that can lead a physician to is a major reason why the disorder is often misdiagnosed suspect porphyria include new-onset hypertension in and underdiagnosed. We often come across patients who a young patient, proximal muscle weakness, or dark or have been misdiagnosed for many years. Some of the more reddish-brown urine.3 common misdiagnoses are appendicitis and cholecystitis; other patients are told they have a urinary tract infection, H&O How is the disease diagnosed? colitis, or another common condition. Many patients actually have multiple surgeries before the diagnosis is MB The most important diagnostic test for acute hepatic established. porphyria is PBG. This can be done on a spot sample of urine; there is no need to waste valuable time by collecting H&O What treatments are used for acute a 24-hour sample. If urine PBG is elevated, the patient porphyria? has an acute hepatic porphyria. This is a highly sensitive test because urine PBG typically is elevated during an MB The most important step is to stabilize patients, and acute attack. address symptoms such as nausea, vomiting, hypertension, Second-line testing is available to determine the and electrolyte imbalances such as hyponatremia. Patients specific type of acute porphyria, although knowing also should be treated for their pain, which is severe—I the type is not necessary at the time of initial diagnosis would like to emphasize that many of these patients are because treatment for acute symptoms for all the forms undertreated for their pain. All patients need to have a is identical. careful history taken to identify what triggering factors Genetic testing can be used as a confirmatory test might be involved. All offending drugs and other factors for the diagnosis. Gene sequencing is available for all should be removed. of the genes involved in acute hepatic porphyria. This In the past, 10% dextrose solution was used as first- is important not just to establish the diagnosis in the line treatment for these patients, but more recently we patient, but for testing family members. have switched to
Recommended publications
  • Liver Transplantation for the Management of Acute Intermittent
    nd Gas y a tro g in lo t o e t s a t i p n Journal of Hepatology and e a l H D f i o s Kappus at al., J Hepatol Gastroint Dis 2017, 3:1 l o a r d ISSN:n 2475-3181 r e u r s o J Gastrointestinal Disorders DOI: 10.4172/2475-3181.1000141 Case Report Open Access Liver Transplantation for the Management of Acute Intermittent Porphyria: A Case Report Matthew R Kappus1, Bryant B Summers2, Jennifer S Byrns2*, Carl L Berg1 and Julius M Wilder1 1Division of Gastroenterology, Duke University School of Medicine, Durham NC, United States 2Department of Pharmacy, Duke University Hospital, Durham NC, United States *Corresponding author: Jennifer S Byrns, Department of Pharmacy, Duke University Hospital, DUMC BOX 3089, Durham, NC 27710, United States, Tel: 919-681-0677; E-mail: [email protected] Received date: December 27, 2016; Accepted date: January 16, 2017; Published date: January 20, 2017 Copyright: © 2017 Kappus MR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract We report a single patient with acute intermittent porphyria whose porphyria was successfully treated with orthotopic liver transplantation. She had a very poor quality of life as a result of years of frequent acute porphyria symptoms manifesting as abdominal pain crises. After transplantation, clinical signs of porphyria resolved as expected. This case adds to a growing body of literature which is assisting to formulate the indications for, and the timing of, transplantation for AIP.
    [Show full text]
  • Hereditary Corpoporphyria Presenting with Deep Jaundice and Photosensitivity
    ANNALS OF GASTROENTEROLOGY 2001, 14(4):319-324 Case report Hereditary corpoporphyria presenting with deep jaundice and photosensitivity D. Kapetanos, P. Xiarhos, E. Kapetis1, A. Avgerinos, A. Ilias, G. Kokozidis, G. Kitis CASE REPORT SUMMARY A 20-year old woman was referred to our department Hereditary coproporphyria is a rare hepatic porphyria with from another hospital in May 2000, due to painless jaun- symptoms similar to acute intermittent porphyria. Photo- dice and pruritus. She reported having dark urine and sensitivity is not described in the latter. We report the case pale stools for two weeks and jaundice for 10 days be- of a young female with deep jaundice, photosensitivity, ane- fore admission. mia, renal failure and no abdominal pain. Hereditary co- proporphyria was diagnosed and the patient was discharged The patient had no past medical history, with no ne- after 111 days in full recovery. She was readmitted after 45 onatal jaundice, had received no medications during the days with abdominal pain and no jaundice or photosensi- previous months and had no alcohol consumption in the tivity. Severe neuropathy developed which caused tetrapare- past. She was on a diet in order to lose weight (her initial sis and deterioration of the respiratory muscle function. weight was 80 kg) and had been using home insecticides Haem arginate was administered with gradual improvement several days before. Her parents reported a family histo- of neuropathy. ry of thalassemia major. Key words: Hereditary corpoporphyria, jaundice, photosen- On admission she was icteric. She had 2-3 blisters on sitivity, neuropathy, haem arginate her face with serous yellow colored fluid.
    [Show full text]
  • Module 01: Classification of Porphyria
    MODULE 01 Classification of Porphyria Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 20120199 Alnylam PharmaceuticalsPharmaceuticals,, Inc.Inc. All rights reserved. -USA-00001-092018 1 Porphyria—A Rare Disease of Clinical Consequence • Porphyria is a group of at least 8 metabolic disorders1,2 – Each subtype of porphyria involves a genetic defect in a heme biosynthesis pathway enzyme1,2 – The subtypes of porphyria are associated with distinct signs and symptoms in patient populations that can differ by gender and age1,3 • Prevalence of some subtypes of porphyria may be higher than generally assumed3 Estimated Prevalence of Most Common Subtypes of Porphyria1,4 Estimated Prevalence Based on European Subtype of Porphyria and US Data Porphyria cutanea tarda (PCT) 1/10,000 (EU)1 0.118-1/20,000 (EU)1,4 Acute intermittent porphyria (AIP) 5/100,000 (US)1 Erythropoietic protoporphyria (EPP) 1/50,000-75,000 (EU)1 1. Ramanujam V-MS, Anderson KE. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26. 2. Puy H et al. Lancet. 2010;375:924-937. 3. Bissell DM et al. N Engl J Med. 2017;377:862-872. 4. Elder G et al. J Inherit Metab Dis. 2013;36:848-857. Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. -USA-00001-092018 2 Classification of Porphyria Porphyria can be classified in 2 major ways1,2: 1 According to major physiological sites: liver or 2 According to major clinical manifestations1,2 bone marrow1,2 • Heme precursors originate in either the liver or Acute Versus Photocutaneous Porphyria bone marrow, which are the tissues most • Major clinical manifestations are either neurovisceral active in heme biosynthesis1,2 symptoms (eg, severe, diffuse abdominal pain) associated with acute exacerbations or cutaneous lesions resulting from phototoxicity1,2 • Acute hepatic porphyria may be somewhat of a misnomer since the clinical features may be prolonged and chronic3 1.
    [Show full text]
  • A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria
    A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria Chengyuan Song Shandong University Qilu Hospital Shaowei Sang Shandong University Qilu Hospital Yuan Liu ( [email protected] ) Shandong University Qilu Hospital https://orcid.org/0000-0003-4991-552X Research Keywords: acute hepatic porphyria, urinary urobilinogen, serum total bilirubin Posted Date: June 14th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-587707/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Background: Due to its variable symptoms and nonspecic laboratory test results during routine examinations, acute hepatic porphyria (AHP) has always been a diagnostic dilemma for physicians. Misdiagnoses, missed diagnoses, and inappropriate treatments are very common. Correct diagnosis mainly depends on the detection of a high urinary porphobilinogen (PBG) level, which is not a routine test performed in the clinic and highly relies on the physician’s awareness of AHP. Therefore, identifying a more convenient indicator for use during routine examinations is required to improve the diagnosis of AHP. Results: In the present study, we retrospectively analyzed laboratory examinations in 12 AHP patients and 100 patients with abdominal pain of other causes as the control groups between 2015 and 2021. Compared with the control groups, AHP patients showed a signicantly higher urinary urobilinogen level during the urinalysis (P < 0.05). However, we showed that the higher urobilinogen level was caused by a false- positive result due to a higher level of urine PBG in the AHP patients. Hence, we used serum total bilirubin, an upstream substance of urinary urobilinogen synthesis, for calibration.
    [Show full text]
  • Acute Intermittent Porphyria: an Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators
    International Journal of Molecular Sciences Review Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators Helene J. Bustad 1 , Juha P. Kallio 1 , Marta Vorland 2, Valeria Fiorentino 3 , Sverre Sandberg 2,4, Caroline Schmitt 3,5, Aasne K. Aarsand 2,4,* and Aurora Martinez 1,* 1 Department of Biomedicine, University of Bergen, 5020 Bergen, Norway; [email protected] (H.J.B.); [email protected] (J.P.K.) 2 Norwegian Porphyria Centre (NAPOS), Department for Medical Biochemistry and Pharmacology, Haukeland University Hospital, 5021 Bergen, Norway; [email protected] (M.V.); [email protected] (S.S.) 3 INSERM U1149, Center for Research on Inflammation (CRI), Université de Paris, 75018 Paris, France; valeria.fi[email protected] (V.F.); [email protected] (C.S.) 4 Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, 5009 Bergen, Norway 5 Assistance Publique Hôpitaux de Paris (AP-HP), Centre Français des Porphyries, Hôpital Louis Mourier, 92700 Colombes, France * Correspondence: [email protected] (A.K.A.); [email protected] (A.M.) Abstract: Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease with low clinical penetrance, caused by mutations in the hydroxymethylbilane synthase (HMBS) gene, which encodes the third enzyme in the haem biosynthesis pathway. In susceptible HMBS mutation carriers, triggering factors such as hormonal changes and commonly used drugs induce an overproduction Citation: Bustad, H.J.; Kallio, J.P.; and accumulation of toxic haem precursors in the liver. Clinically, this presents as acute attacks Vorland, M.; Fiorentino, V.; Sandberg, characterised by severe abdominal pain and a wide array of neurological and psychiatric symptoms, S.; Schmitt, C.; Aarsand, A.K.; and, in the long-term setting, the development of primary liver cancer, hypertension and kidney Martinez, A.
    [Show full text]
  • Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.09.20052449; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria Aaron Cohen, MD, MS 1, Steven Chamberlin, ND 1, Thomas Deloughery, MD 1, Michelle Nguyen, BS 1, Steven Bedrick, PhD 1, Stephen Meninger, PharmD 2, John J. Ko, PharmD, MS 2, Jigar Amin, PharmD 2, Alex Wei, PharmD 2, William Hersh, MD 1 1Department of Medical Informatics & Clinical Epidemiology, School of Medicine, Oregon Health & Science University, Portland, OR USA. 2Alnylam Pharmaceuticals, Cambridge, MA, USA. Abstract Background With the growing adoption of the electronic health record (EHR) worldwide over the last decade, new opportunities exist for leveraging EHR data for detection of rare diseases. Rare diseases are often not diagnosed or delayed in diagnosis by clinicians who encounter them infrequently. One such rare disease that may be amenable to EHR-based detection is acute hepatic porphyria (AHP). AHP consists of a family of rare, metabolic diseases characterized by potentially life-threatening acute attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life. The goal of this study was to apply machine learning and knowledge engineering to a large extract of EHR data to determine whether they could be effective in identifying patients not previously tested for AHP who should receive a proper diagnostic workup for AHP.
    [Show full text]
  • The Little Imitator-Porphyria: a Neuropsychiatric Disorder
    Journal ofNeurology, Neurosurgery, and Psychiatry 1997;62:319-328 319 REVIEW J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.62.4.319 on 1 April 1997. Downloaded from The little imitator-porphyria: a neuropsychiatric disorder Helen L Crimlisk Abstract Porphyria is derived from the Greek word por- Three common subtypes of porphyria phuros meaning purple. Protoporphyrin IX is give rise to neuropsychiatric disorders; the biologically active substance, an important acute intermittent porphyria, variegate feature of which is its metal binding capacity. porphyria, and coproporphyria. The sec- Both chlorophyll and haem are metallopor- ond two also give rise to cutaneous symp- phyrins and are involved in the processes of toms. Neurological or psychiatric energy capture and utilisation in animals and symptoms occur in most acute attacks, plants. The description of the porphyrins by and may mimc many other disorders. Nobel laureate Hans Fischer' in 1930 as: The diagnosis may be missed because it is "The compounds which make grass green not even considered or because of techni- and blood red." cal problems, such as sample collection indicates the central position of these sub- and storage, and interpretation of results. stances in the biological sciences. A negative screening test does not exclude The porphyrias are a heterogeneous group the diagnosis. Porphyria may be overrep- of overproduction diseases, resulting from resented in psychiatric populations, but genetically determined, partial deficiencies in the lack of control groups makes this haem biosynthetic enzymes. Their manifesta- Department of uncertain. The management of patients tions are broad and their relevance in neu- Neuropsychiatry, with porphyria and psychiatric symptoms ropsychiatric disorders may sometimes be Institute ofNeurology, causes considerable Queen Square, problems.
    [Show full text]
  • Molecular Genetics of Variegate Porphyria in Finland
    Department of Medicine, Division of Endocrinology University of Helsinki, Finland MOLECULAR GENETICS OF VARIEGATE PORPHYRIA IN FINLAND Mikael von und zu Fraunberg Academic dissertation To be presented with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium II, Haartmaninkatu 8, Biomedicum Helsinki, on March 22th 2003, at 12:00 noon Helsinki 2003 SUPERVISED BY Docent Raili Kauppinen, M.D., Ph.D. Department of Medicine Division of Endocrinology University of Helsinki Finland REVIEWED BY Professor Richard J. Hift, M.D., Ph.D. Department of Medicine Lennox Eales Porphyria Laboratory MRC/UCT Liver Research Centre University of Cape Town South Africa and Professor Eeva-Riitta Savolainen, M.D., Ph.D. Department of Clinical Chemistry University of Oulu Finland OFFICIAL OPPONENT: Docent Katriina Aalto-Setälä, M.D., Ph.D. Department of Medicine University of Tampere Finland © Mikael von und zu Fraunberg ISBN 952-91-5643-X (paperback) ISBN 952-10-0970-5 (pdf) http://ethesis.helsinki.fi Helsinki 2003 Yliopistopaino to my family CONTENTS SUMMARY............................................................................................................... 6 ORIGINAL PUBLICATIONS................................................................................... 8 ABBREVIATIONS.................................................................................................... 9 INTRODUCTION ................................................................................................... 10 REVIEW
    [Show full text]
  • Acute Hepatic Porphyria Neuro-Visceral Crisis
    :: Acute hepatic porphyria neuro-visceral crisis - This document is a translation of the French recommendations drafted by Prof. Jean-Charles Deybach and Dr. Hervé Puy, reviewed and published by Orphanet in 2007. - Some of the procedures mentioned, particularly drug treatments, may not be validated in the country where you practice. - See also the emergency guidelines for cutaneous porphyrias Synonyms: Acute intermittent porphyria, Hereditary coproporphyria, Porphyria variegata Definition: Porphyrias are monogenic and autosomal genetic conditions and each is linked to a deficiency of haem metabolising enzymes. Acute porphyria with abdominal pain and/or neuro-psychiatric symptoms can cause serious emergencies and include: - Acute intermittent porphyria (AIP), - Hereditary coproporphyria (HC), - Porphyria variegata (PV). Porphyria variegata and Hereditary coproporphyria can have mixed cutaneous and/or neuro-psychiatric symptoms. Further information: See the Orphanet abstract Menu Pre-hospital emergency care Recommendations for hospital recommendations emergency departments Synonyms Emergency situations Aetiology Drug interactions Special risks in an emergency Anaesthesia Frequently used long term treatments Additional therapeutic measures and hospitalisation Complications Organ donation Specific medical care prior to hospitalisation Documentary resources For further information Pre-hospital emergency care recommendations Call for a patient suffering from acute hepatic porphyria neuro-visceral crisis Synonyms ` Acute intermittent porphyria,
    [Show full text]
  • Molecular Characterisation of Acute Intermittent Porphyria in South Africa…………
    MOLECULAR CHARACTERISATION OF ACUTE INTERMITTENT PORPHYRIA IN SOUTH AFRICA BY PHILIP HENDRIK FORTGENS STUDENT NUMBER: FRTPHI001 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In partial fulfilment of the requirements for the degree MMed (Chemical Pathology) Faculty of Health Sciences UniversityUNIVERSITY of OF CAPECape TOWN Town Date of submission: 17 February 2014 Supervisor: Prof P Meissner Division of Medical Biochemistry University of Cape Town The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town Declaration I, Philip Hendrik Fortgens, hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it, as been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature:……………………………………….. Date:…………………………………………….. 2 Table of Contents Declaration………………………………………………………………………………… 2 Acknowledgements……………………………………………………………………….. 7 List of Abbreviations……………………………………………………………………... 8 PART A………………………………………………………………………………………..
    [Show full text]
  • An Inherited Enzymatic Defect in Porphyria Cutanea Tarda: Decreased Uroporphyrinogen Decarboxylase Activity
    An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J P Kushner, … , A J Barbuto, G R Lee J Clin Invest. 1976;58(5):1089-1097. https://doi.org/10.1172/JCI108560. Research Article Uroporphyrinogen decarboxylase activity was measured in liver and erythrocytes of normal subjects and in patients with porphyria cutanea tarda and their relatives. In patients with porphyria cutanea tarda, hepatic uroporphyrinogen decarboxylase activity was significantly reduced (mean 0.43 U/mg protein; range 0.25-0.99) as compared to normal subjects (mean 1.61 U/mg protein; range 1.27-2.42). Erythrocyte uroporphyrinogen decarboxylase was also decreased in patients with porphyria cutanea tarda. The mean erythrocyte enzymatic activity in male patients was 0.23 U/mg Hb (range 0.16-0.30) and in female patients was 0.17 U/mg Hb (range 0.15-0.18) as compared with mean values in normal subjects of 0.38 U/mg Hb (range 0.33-0.45) in men and 0.26 U/mg Hb (range 0.18-0.36) in women. With the erythrocyte assay, multiple examples of decreased uroporphyrinogen decarboxylase activity were detected in members of three families of patients with porphyria cutanea tarda. In two of these families subclinical porphyria was also recognized. The inheritance pattern was consistant with an autosomal dominant trait. The difference in erythrocyte enzymatic activity between men and women was not explained but could have been due to estrogens. This possibility was supported by the observation that men under therapy with estrogens for carcinoma of the prostate had values in the normal female range.
    [Show full text]
  • Highly Specialised Technology Evaluation Givosiran For
    Highly Specialised Technology Evaluation Givosiran for treating acute hepatic porphyria [ID1549] Evaluation Report © National Institute for Health and Care Excellence 2021. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Highly Specialised Technology Evaluation Givosiran for treating acute hepatic porphyria [ID1549] Contents: The following documents are made available to consultees and commentators: The final scope and final stakeholder list are available on the NICE website. 1. Company submission from Alnylam 2. Company clarification response 3. Consultee submissions from: a. British Porphyria Association: i. Submission ii. Supporting document on patient case studies b. Global Porphyria Advocacy Coalition submission c. National Acute Porphyria Service, Cardiff and Vale UHB d. National Acute Porphyria Service, King’s College Hospital NHS Foundation Trust e. NHS England and Improvement 4. Evidence Review Group report prepared by PenTAG 5. Evidence Review Group report – factual accuracy check 6. Evidence Review Group addendum Please note that the appendices to the company’s submission and company model will be available as a separate file on NICE Docs for information only. Any information supplied to NICE which has been marked as confidential has been redacted. All personal information has also been redacted. © National Institute for Health and Care Excellence
    [Show full text]